Icon forecasts revenue growth of up to 10%

Pharmaceutical services provider Icon is forecasting revenue growth of up to 10% this year, on the back of a better-than-expected 2013 financial performance.

The Dublin-based firm yesterday reported a 20% increase in annual revenue, for 2013, to $1.34bn (€980m).

In the second half of last year, the Nasdaq-quoted firm increased its revenue guidance twice; most recently in October — to a range of $1.32bn to $1.33bn. Yesterday’s figures also showed an 82% rise in full-year net profit (before exceptional items) to $110m and earnings per share — before restructuring and other items — of $1.77 per share, up from $1 in 2012.